Medisi America
  • Home
  • We Are
  • Services
  • News
  • Contact Us
  • en EN
    • en EN
    • fr FR
    • de DE
    • it IT
    • pt PT
    • ru RU
    • es ES

COFEPRIS Challenges 2020

By Medisi America on 21 febrero, 2020

Since December 1st, 2018 a historical change in administration that consisted of a new president who is committed to Public Office cleansing of corrupt and unequal practices had a strong impact on the whole country course of operation. Many institutions were eliminated or were audited and restructured. 

Cofepris was audited and analyzed for permanence or removal but was decided to stay active. This, however, caused a complete pause in real operation for almost a whole Quarter of the year; therefore in between 2019-2020, we observed a complete change in staff and certain evaluation criteria.

The main changes to this day include grouping criteria, better answering time for traditional track processes versus previous years and a tendency to avoid any preferential treatment tracks (like Third Authorized Party processes).

Despite initial setbacks, right now answering times are becoming much better than in any previous years which becomes a strong solution given by this administration.

-Copyright 2020 Medisi America. Replication and quote of this content are subject to International Author Law.

Posted in News.
Share
←  NewerCOFEPRIS Evolves
Older  →ResMed ventilators recall is Class I

Entradas recientes

  • COFEPRIS Evolves
  • COFEPRIS Challenges 2020
  • ResMed ventilators recall is Class I
  • Finding a non-invasive way to predict effectiveness of cancer therapy.

NEWS

  • Conferences
  • News
  • Science
  • Technology

Deja una respuesta Cancelar la respuesta

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

Related Posts

  • 30 diciembre, 2019

    Medical Devices; Exemptions From Premarket Notification for Class I and Class II Devices

    «The Food and Drug Administration (FDA, Agency) identified a list of class I devices and class II devices that are now exempt from premarket notification requirements, subject to certain limitations. FDA published the lists of final determinations in accordance with procedures established by the 21stCentury Cures Act (Cures Act). Although each classification regulation for each …

  • 18 junio, 2019

    Artificial intelligence better than humans at spotting lung cáncer

    Researchers have used a deep-learning algorithm to detect lung cancer accurately from computed tomography scans. The results of the study indicate that artificial intelligence can outperform human evaluation of these scans. If you want to read more about this news click here.

  • 10 octubre, 2019

    Human trials could start soon on Adam’s 3D printed bone grafts

    Adam — a young company with technology to 3D print bone grafts made out of ceramic bioglass and modified biopolymer — said today that it expects first human trials to start by the end of the year. Officials at the Groton, Conn.– and Odessa, Ukraine–based company expect preclinical trials to finish this month. The Adam technology …

  • 18 junio, 2019

    5 Pediatric Orthopedic Devices you need to know

    The National Capital Consortium for Pediatric Device Innovation recently recognized five pediatric orthopedic devices that could improve scoliosis treatment, clubfoot assessment, and surgical imaging. If you want to read more about this news click here.

  • © 2026 MEDISI America - All rights reserved
  • Home
  • We Are
  • Services
  • News
  • Contact Us
  • en EN
    • en EN
    • fr FR
    • de DE
    • it IT
    • pt PT
    • ru RU
    • es ES